Zoetis (ZTS) earnings call transcripts

Management framed the reset as a response to worsening companion-animal demand and promotional competition, while stressing disciplined defense of share and long-term portfolio value.

Management framed the quarter as a sharper-than-expected companion-animal slowdown, requiring near-term commercial and cost actions before innovation accelerates in 2027–28.

Management framed 2026 as a year of disciplined execution amid US consumer pressure and aggressive launch promotions, with conditions expected to moderate as the year progresses.

Management framed the quarter as a moderation driven by weaker therapeutic clinic visits and a strong comparison, while emphasizing resilience in livestock and alternative channels.

Management framed the quarter as broad-based execution supporting a raised outlook, while stressing durable franchise expansion despite Librela adoption challenges.

Management framed Zoetis as resilient amid macro and policy uncertainty, while acknowledging slower-than-expected OA pain adoption and newly embedded tariff costs.

Management framed 2025 as continued above-market growth, supported by durable franchises and innovation, while acknowledging competition and foreign-exchange pressure.

Management framed the quarter as broad-based growth powered by differentiated franchises, with Librela’s launch and category expansion the clearest long-term opportunity.

Management framed the raised outlook as execution-led, with innovation and market expansion outweighing persistent macro headwinds and planned growth investments.

Management framed the raised outlook as evidence of resilient demand, with companion innovation driving growth despite mixed comparisons and market headwinds.

Management framed 2024 as continued above-market growth, with Librela accelerating and product investment prioritized despite FX and competitive uncertainty.